[HTML][HTML] Current strategies of antiviral drug discovery for COVID-19

M Mei, X Tan - Frontiers in Molecular Biosciences, 2021 - frontiersin.org
SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as
Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been …

[HTML][HTML] Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

R Yamin, AT Jones, HH Hoffmann, A Schäfer, KS Kao… - Nature, 2021 - nature.com
Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated
clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing …

Highly active engineered IgG3 antibodies against SARS-CoV-2

S Kallolimath, L Sun, R Palt, K Stiasny… - Proceedings of the …, 2021 - National Acad Sciences
Monoclonal antibodies (mAbs) that efficiently neutralize SARS-CoV-2 have been developed
at an unprecedented speed. Notwithstanding, there is a vague understanding of the various …

[HTML][HTML] Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches

NK Jha, M Jeyaraman, M Rachamalla, S Ojha, K Dua… - Immuno, 2021 - mdpi.com
An outbreak of “Pneumonia of Unknown Etiology” occurred in Wuhan, China, in late
December 2019. Later, the agent factor was identified and coined as severe acute …

[HTML][HTML] Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson… - Cell Reports …, 2021 - cell.com
The continual emergence of novel coronaviruses (CoV), such as severe acute respiratory
syndrome-(SARS)-CoV-2, highlights the critical need for broadly reactive therapeutics and …

Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma

H Natarajan, AR Crowley, SE Butler, S Xu, JA Weiner… - MBio, 2021 - Am Soc Microbiol
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but
the antibody characteristics that contribute to efficacy remain poorly understood. This study …

Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike

AR Crowley, H Natarajan, AP Hederman, CA Bobak… - Elife, 2022 - elifesciences.org
Preexisting antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2
have the potential to influence the antibody response to COVID-19 vaccination and infection …

[HTML][HTML] Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein

O Staufer, K Gupta, JE Hernandez Bücher… - Nature …, 2022 - nature.com
SARS-CoV-2 infection is a major global public health concern with incompletely understood
pathogenesis. The SARS-CoV-2 spike (S) glycoprotein comprises a highly conserved free …

[HTML][HTML] Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization

AA Hennrich, B Sawatsky, R Santos-Mandujano… - PLoS …, 2021 - journals.plos.org
Vaccines of outstanding efficiency, safety, and public acceptance are needed to halt the
current SARS-CoV-2 pandemic. Concerns include potential side effects caused by the …

Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection

BM Gunn, S Bai - Human vaccines & immunotherapeutics, 2021 - Taylor & Francis
Antibodies can provide antiviral protection through neutralization and recruitment of innate
effector functions through the Fc domain. While neutralization has long been appreciated for …